NBI-1117567, an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist, is intended for the potential treatment of neurological and neuropsychiatric conditions.
Eiry W Roberts, M.D.,
.
(C) 2024 M2 COMMUNICATIONS, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
135 USD | +1.43% | -0.32% | +2.44% |
NBI-1117567, an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist, is intended for the potential treatment of neurological and neuropsychiatric conditions.
Eiry W Roberts, M.D.,
.
(C) 2024 M2 COMMUNICATIONS, source
1st Jan change | Capi. | |
---|---|---|
+2.44% | 13.58B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+1.34% | 22.78B | |
-11.09% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+27.89% | 11.66B | |
+83.45% | 9.17B |